Atossa Q3 Revenues Fall 27 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics reported on Tuesday that revenues in its third quarter dropped 27 percent year over year.

It also said it inked a new deal with Aspire Capital for the sale of up to $25 million in common stock during the next 30 months.

For the three months ended Sept. 30, Atossa posted $76,597 in revenues, down from $105,576 a year ago. Diagnostic testing service revenues slipped to $72,187 from $104,011, while product sales increased to $4,400 from $1,565.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."